The therapeutic benefits of heme oxygenase (HO-1) inhibition in the management of systemic malignancies besides hepatocellular carcinomas.
Shailendra
S
Kapoor
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000201:enzymology; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051547:Heme Oxygenase-1 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000201:enzymology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000201:enzymology; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000201:enzymology; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D010879:Piperazines / Q000494:pharmacology; D011524:Protoporphyrins / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000201:enzymology
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011524:Protoporphyrins; D011743:Pyrimidines; C017803:zinc protoporphyrin; D000068877:Imatinib Mesylate; D051547:Heme Oxygenase-1